Bharath Kumar

In a pragmatic trial conducted in general medical wards with limited diagnostic and therapeutic resources in Kenya, glucocorticoids reduced mortality in patients with community-acquired pneumonia. Full SONIA trial results: nej.md/47glh02

#MedSky #PulmSky #CriticalCare

Incredible global effort- glad sites from India could collaborate- can't wait to see the results!

Congratulations @dogicuma.bsky.social and the entire global MegaROX team 🙏

#MegaROXtrial 27 to go. 39973 enrolled.

ICU-acquired weakness is common; protocolised active rehabilitation helps, while higher enteral protein alone shows no outcome benefit. Priorities include early prognostic markers, better diagnostics and personalised care. zurl.co/BBlDf

The #MegaROXtrial has fewer than 150 patients left to enrol

The intensive care medicine research agenda for the management of ICU acquired weakness: a multinational, interprofessional perspective

CCR Journal Watch
https://criticalcarereviews.com/latest-evidence/journal-watch

The #MegaROXtrial has 39800 patients which leaves only 200 left to enrol

Using robust methods, we arrived at a core set of outcomes that we recommend all clinical trials in dengue collect data on. Work led by Sophie Yacoub, Daniel Munblit and Laura Merson @isaric1.bsky.social

Core outcome measurement set for clinical trials in dengue: an international Delphi consensus study (DEN-CORE) Dengue, caused by any one of four distinct virus serotypes, is the most rapidly spreading mosquito-borne viral disease worldwide. It is a primary arboviral infection with increasing global incidence, ...

Our paper on a core outcome measurement set for clinical trials in dengue is now published in The Lancet Infectious Diseases : www.thelancet.com/journals/lan...

Dengue outbreak in Sudan 👇. We need better tools and investment to tackle dengue

This👇 …. often unseen but crucial role

##MegaROXtrial 1600 to go

I seem to have been discussing pilot and feasibility studies a lot this week. One question often asked is how big should my pilot/feasibility study be? 1/6
#MethodologyMonday #124

The #MegaROXtrial has reached 37851 enrolments. 38k likely next week and 40k on the cards for Nov.

There has been a lot of debate recently about the promise of real world data - the routine (observational) data collected on patients eg  treatments received, clinical outcomes etc – for estimating treatment effects. But can they deliver? 1/9
#MethodologyMonday #123

#MegaROXtrial 2.5K to go

I am delighted to be joining the Editorial Board of @bmj.com as a freelance Clinical Editorial Advisor. I look forward to bringing acute/critical care and LMIC perspectives to the editorial decision-making table.

One of the most elegant and sucint text on global critical care research inequity

#DecolonizeGH

Giant Great Grant - "3G" - ESICM The 2nd edition of the 3G project is now open - thanks to the support of Biomérieux. We call on all healthcare professionals to submit a proposal focusing on FAST ID/AST to implement antimicrobial stewardship in critically ill patients.

🚨 The #ESICM 𝟯𝗚 𝗚𝗿𝗮𝗻𝘁 – 2nd Call is 𝗢𝗣𝗘𝗡 𝘂𝗻𝘁𝗶𝗹 𝟮𝟳 𝗔𝘂𝗴! 💶 €300K for research on 𝗿𝗮𝗽𝗶𝗱 𝗶𝗻𝗳𝗲𝗰𝘁𝗶𝗼𝗻 𝗱𝗶𝗮𝗴𝗻𝗼𝘀𝘁𝗶𝗰𝘀 𝗶𝗻 𝘁𝗵𝗲 #ICU, in collaboration with bioMérieux!

We invite bold, hypothesis-driven proposals with real-world impact on #AMR & patient outcomes.

🔗 www.esicm.org/3g-giant-gre...

#ICUresearch

The 37000th patient was enrolled in the #MegaROXtrial in Casey Hospital, Australia at 05:01am local time. 3K to go.

The #MegaROXtrial has 36907 patients enrolled. 37K is days away. We will get to 40K in the last quarter of 2025.

We often now hear the term “Bayesian borrowing” in trials. But what is Bayesian borrowing and what are the pros and cons around its use? 1/6
#MethodologyMonday #122

Heat waves make the news when they impact Global North countries

Constant, extreme heat is a daily fact of life for billions in the Global South

36500 patients enrolled in the #MegaROXtrial. Only 3500 to go.

Our pilot trial evaluating dexamethasone in patients hospitalised with dengue is now active at 5 hospitals and we enrolled our 5th trial participant today.

We are funded by @uoftcities.bsky.social and the University of Toronto India foundation. Trial sponsored by @georgeinstitute.bsky.social

Persistent Critical Illness Among Intensive Care Patients in India: A Registry-Embedded Cohort Study - PubMed In this cohort of critically ill patients in India, as ICU stay increased, the prognostic performance of acute illness characteristics decreased whereas that of antecedent characteristics remained poo...

Very interesting- please also see our work from India recently published in CCM: pubmed.ncbi.nlm.nih.gov/40521972/

Over recent weeks I have heard about some trials struggling with the phenomenon known as “Lasagne’s Law.” I’ve flagged this issue before, but always good to revisit it and discuss what can be done to minimise it 1/7
#MethodologyMonday #121

This is a fantastic opportunity: isaric.org/capacity/sci...

Please share widely 🙏